We demonstrate here for the first time that SGLT2i therapy increased islet insulin content, and decreased proinsulin levels through reduction in β-cell oxidative and ER stress in mouse models of monogenic NDM and obese/T2D. Here, INS is linked to type 2 diabetes mellitus.